A Phase 3, Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Chenodeoxycholic Acid (CDCA), With an Open-Label Cohort, in Newly Diagnosed Participants With Cerebrotendinous Xanthomatosis (CTX)
Latest Information Update: 22 Nov 2024
At a glance
- Drugs Chenodeoxycholic acid (Primary)
- Indications Cerebrotendinous xanthomatosis
- Focus Registrational; Therapeutic Use
- Sponsors Leadiant Biosciences
Most Recent Events
- 18 Nov 2024 Status changed from active, no longer recruiting to withdrawn prior to enrolment.
- 28 May 2024 Status changed from not yet recruiting to active, no longer recruiting.
- 20 Feb 2024 New trial record